Jan. 30 Financial Quick Takes: Vertex, Black Diamond, Alexion, Alector, DBV
Trikafta sales bolster Vertex’s revenue
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) handily beat consensus estimates with its 4Q19 earnings Thursday, bolstered by the $420 million in sales newly approved CF therapy Trikafta elexacaftor/tezacaftor/ivacaftor